Philips Respironics Recall Notice:
Philips Respironics issued a Recall Notification for some CPAP and BiLevel PAP devices and mechanical ventilators due to potential health risks related to foam used in the devices. To learn more, visit the Philips Website and review FDA’s Safety Communication and FAQs. For questions about the Philips recall, please contact Philips at 1-877-907-7508.
The Northside Hospital Cancer Institute Prostate & Urologic Cancer Program diagnoses and/or treats more new prostate cancer patients than any other community hospital in Georgia-ranking among the top prostate cancer programs in the country. We also have one of the largest programs in the nation for the diagnosis and/or treatment of bladder cancer.
Urologic cancers, which include cancers of the prostate, kidneys, bladder, penis and testicles, are complex diseases for which multiple treatment options exist. Our Prostate & Urologic Cancer Program’s multidisciplinary team of specialists work together utilizing a coordinated team approach to yield higher rates of treatment success.
Prostate cancer is the second most common cancer in American men and will affect one in every nine men. The risk of prostate cancer is 74 percent higher in black men than in white men for reasons that remain unclear. Additionally, this year over 76,000 people will be diagnosed with kidney cancer in the United States. Kidney cancer incidence rates appear to have stabilized since the mid-2000s following decades of increase, in part due to a rise in incidental detection because of the increased use of medical imaging. Bladder cancer is the fourth most common cancer among men and the ninth most common among women in the United States. Bladder cancer incidence is increasing both nationally and here in Georgia. In 2020, over 2,000 Georgians were diagnosed with bladder cancer.
Northside Hospital Cancer Institute’s Prostate & Urologic Cancer Program offers specialized cancer care for patients diagnosed with:Open clinical trials & research information for prostate and urologic cancers